CN104718190B - 用于光动力疗法的吡啶酮化合物 - Google Patents

用于光动力疗法的吡啶酮化合物 Download PDF

Info

Publication number
CN104718190B
CN104718190B CN201380053228.0A CN201380053228A CN104718190B CN 104718190 B CN104718190 B CN 104718190B CN 201380053228 A CN201380053228 A CN 201380053228A CN 104718190 B CN104718190 B CN 104718190B
Authority
CN
China
Prior art keywords
compound
formula
ala
photodynamic therapy
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380053228.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104718190A (zh
Inventor
A·克尔诺
M·伍德
A·派瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Exeter
Original Assignee
University of Exeter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Exeter filed Critical University of Exeter
Publication of CN104718190A publication Critical patent/CN104718190A/zh
Application granted granted Critical
Publication of CN104718190B publication Critical patent/CN104718190B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/81—Preparation or application process involves irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN201380053228.0A 2012-09-03 2013-09-02 用于光动力疗法的吡啶酮化合物 Expired - Fee Related CN104718190B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1215675.8A GB201215675D0 (en) 2012-09-03 2012-09-03 Compound
GB1215675.8 2012-09-03
PCT/GB2013/052297 WO2014033477A1 (en) 2012-09-03 2013-09-02 Pyridinone compounds for use in photodynamic therapy

Publications (2)

Publication Number Publication Date
CN104718190A CN104718190A (zh) 2015-06-17
CN104718190B true CN104718190B (zh) 2017-03-08

Family

ID=47075165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380053228.0A Expired - Fee Related CN104718190B (zh) 2012-09-03 2013-09-02 用于光动力疗法的吡啶酮化合物

Country Status (15)

Country Link
US (1) US9346758B2 (enExample)
EP (1) EP2892881B1 (enExample)
JP (1) JP2015526499A (enExample)
KR (1) KR20150068374A (enExample)
CN (1) CN104718190B (enExample)
AU (1) AU2013308197B2 (enExample)
BR (1) BR112015004732A2 (enExample)
CA (1) CA2883754A1 (enExample)
GB (1) GB201215675D0 (enExample)
IN (1) IN2015DN02514A (enExample)
MX (1) MX2015002705A (enExample)
RU (1) RU2015111137A (enExample)
SG (1) SG11201501604TA (enExample)
WO (1) WO2014033477A1 (enExample)
ZA (1) ZA201502153B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201215675D0 (en) 2012-09-03 2012-10-17 Univ Exeter Compound
EP3148528A1 (en) 2014-06-02 2017-04-05 University of Exeter Combinations of a photosensitizer with a hydrogen sulfide donor, thioredoxin inhibitor or nitroxide for use in photodynamic therapy
CN112062713B (zh) * 2020-08-04 2023-03-31 浙江工业大学 具铁螯合性和pdt活性的ala-hpo杂合衍生物及其制备方法与应用
KR102265592B1 (ko) * 2020-10-29 2021-06-17 김진왕 5-아미노레불린산 수화염화물을 포함하는 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004498A1 (en) * 1992-08-12 1994-03-03 British Technology Group Ltd. 3-hydroxypyridin-4-one derivatives as chelating agents
CN1318388C (zh) * 2000-07-27 2007-05-30 光治疗公共有限公司 在光化学疗法中作为光敏剂的5－氨基乙酰丙酸的酯类

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5895786A (en) * 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
GB201215675D0 (en) 2012-09-03 2012-10-17 Univ Exeter Compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004498A1 (en) * 1992-08-12 1994-03-03 British Technology Group Ltd. 3-hydroxypyridin-4-one derivatives as chelating agents
CN1318388C (zh) * 2000-07-27 2007-05-30 光治疗公共有限公司 在光化学疗法中作为光敏剂的5－氨基乙酰丙酸的酯类

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis, physicochemical properties and biological evaluation of ester prodrugs of 3-hydroxypyridin-4-ones: design of orally active chelators with clinical potential;Bijaya L. Rai, et.al.;《Eur. J. Med. Chem.》;19990601;第34卷(第6期);475-485 *
The Hydroxypyridinone Iron Chelator CP94 Can Enhance PpIX-induced PDT of Cultured Human Glioma Cells;Emma Blake and Alison Curnow;《Photochemistry and Photobiology》;20100907;第86卷(第5期);1154-1160 *

Also Published As

Publication number Publication date
EP2892881B1 (en) 2017-07-19
ZA201502153B (en) 2017-07-26
GB201215675D0 (en) 2012-10-17
CN104718190A (zh) 2015-06-17
AU2013308197A1 (en) 2015-04-09
WO2014033477A1 (en) 2014-03-06
EP2892881A1 (en) 2015-07-15
MX2015002705A (es) 2015-12-01
KR20150068374A (ko) 2015-06-19
US20150210642A1 (en) 2015-07-30
US9346758B2 (en) 2016-05-24
SG11201501604TA (en) 2015-05-28
BR112015004732A2 (pt) 2018-04-17
JP2015526499A (ja) 2015-09-10
IN2015DN02514A (enExample) 2015-09-11
CA2883754A1 (en) 2014-03-06
RU2015111137A (ru) 2016-10-20
AU2013308197B2 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
EP1313695B1 (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
CN102159553B (zh) 靶向氧氮自由基药剂
US6992107B1 (en) Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
JP6832358B2 (ja) ５−アミノレブリン酸及び誘導体の塩
CN104718190B (zh) 用于光动力疗法的吡啶酮化合物
CN109689060A (zh) 组合化学治疗
KR102699638B1 (ko) 플루오로 치환 포르피린 화합물, 그를 포함하는 약제학적 조성물, 및 그를 제조하고 사용하는 방법
WO2020081839A1 (en) Methods and compositions for treating oral mucositis
US9371275B2 (en) 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis
US20130225545A1 (en) Porphyrin treatment of neurodegenerative diseases
KR102782298B1 (ko) 전이금속이 결합된 보디피계 화합물을 포함하는 초음파 감작제 조성물 및 이의 용도
US20240376155A1 (en) Novel compounds and compositions for targeted therapy of renal cancers
US20060241166A1 (en) Sapphyrins and uses thereof
EA016052B1 (ru) N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ
KR20160019321A (ko) 포르포빌리노겐을 유효성분으로 포함하는 암 치료용 약학적 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170308

Termination date: 20200902